Sanofi has confirmed intermittent supply issues affecting Lantus SoloStar insulin pens due to increased demand. Here's what ...
The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...
(RTTNews) - Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling certain Insulin Glargine (Insulin glargine-yfgn) Injection prefilled pens due to the potential for ...
Mylan and Biocon's Semglee (insulin glargine injection) is now the second approved "follow-on" biologic of Sanofi's Lantus. Adults with Type 2 diabetes, and adult and pediatric patients with Type 1 ...
The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...
SANOFI'S NEW BASAL INSULIN LANTUS XR, KNOWN AS TOUJEO IN THE U.S. AND EUROPE, APPROVED IN JAPAN FOR THE TREATMENT OF DIABETES MELLITUS Paris, France - July 3, 2015 - Sanofi announced today that the ...
Semglee™ (insulin glargine injection; Mylan and Biocon Biologics) is now available to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes.
INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results